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Objective: To evaluate the effect of constraint-induced move-
ment therapy in adult stroke patients and to examine the im-
pact of time since stroke and various treatment modalities. 
Data sources: PubMed, EMBASE, Cochrane and PEDro tri-
al registers were searched for clinical trials published before 
November 2012. 
Study selection: Randomized or quasi-randomized con-
trolled trials of constraint-induced movement therapy last-
ing 2–7 h/day for 8–28 days were included. 
Data extraction: Measurements were classified into the fol-
lowing categories: arm motor function, arm motor activity, 
activities of daily living, and participation. A pooled stand-
ardized mean difference (SMD) was calculated for each 
category. Moderators were: trial quality, behavioural tech-
niques, amount of training, time since stroke, shaping, and 
the nature of the control group. 
Data synthesis: Of 3,842 records initially screened 23 trials 
were included. A small post-treatment effect was found on 
arm motor function (SMD 0.28, 95% confidence interval 
(CI) 0.11–0.44). Meanwhile, a moderate effect on arm mo-
tor activity was found post-treatment (SMD 0.51, 95% CI 
0.30–0.73) and at 3–6 months follow-up (SMD 0.41, 95% CI 
0.08–0.74). 
Conclusion: Constraint-induced movement therapy can im-
prove arm motor function and improve arm motor activities 
and may have a lasting effect on arm motor activity. 
Key words: constraint-induced movement therapy; adult; cere-
bral stroke; meta-analysis; ICF.
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INTRODUCTION 
Paresis of the upper extremity is a common impairment after 
stroke. Even after recovery approximately 20% of survivors 
cannot independently complete upper extremity activities, such 
as feeding and personal care (1). Constraint-induced movement 
therapy (CIMT) is a treatment for mild and moderate upper ex-
tremity motor dysfunction after stroke. The treatment consists 
of intensive exercises for the more affected upper limb. In ad-
dition, different behavioural procedures, such as a behavioural 
contract, systematic feedback and encouragement of real-world 
problem-solving, can be used to enhance the transfer of gained 
motor skills into daily activities. The less affected arm is also 
constrained by a mitt or cast during the course of treatment (2, 
3). The original protocol included 10 days of therapy for 6 h a 
day and was developed for chronic stroke patients (2).
One large clinical trial (4) and 5 systematic reviews on the 
effect of CIMT have been published (5–9). In the large clinical 
trial, the effect of traditional CIMT 3–9 months post-stroke was 
investigated in 222 chronic stroke patients from 7 American sites 
(4). Significant effects on arm motor function, self-reported arm 
use, and self-reported quality of arm use were found. A Cochrane 
systematic review with a subsequent update found reduced arm 
motor impairment (standardized mean difference (SMD) 0.65, 
95% confidence interval (CI) 0.15–1.15), together with increased 
arm motor function (SMD 0.44, 95% CI 0.03–0.84) and perceived 
arm motor function (SMD 1.16, 95% CI 1.05–1.27) after CIMT (7, 
10). Two other recent reviews found an effect of modified CIMT 
compared with traditional rehabilitation on the Fugl-Meyer assess-
ment (mean difference (MD) = 7.80, 95% CI 4.21–11.38), Action 
Research Arm Test (MD = 14.15, 95% CI 10.71–17.59), Wolf 
Motor Function Test (MD = 0.46, 95% CI 0.33–0.59), Functional 
Independence Measure (MD = 7.00, 95% CI 0.75–13.26) and Mo-
tor Activity Log (MAL) (MD = 0.85, 95% CI 0.62–1.08) (8, 9). 
A significant variety of CIMT modifications is present in the 
various trials, which is also evident in the heterogeneity shown 
in earlier reviews (6, 7, 9). CIMT is a multifaceted treatment 
that combines functional training and behavioural treatment. 
In particular, the behavioural procedures are used in different 
ways across trials. Moreover, the trials differ in terms of the 
nature of the control group, the time in therapy, and the time 
from stroke to inclusion. All earlier systematic reviews state 
that the empirical evidence is limited and underpowered. There 
is only one meta-analysis of follow-up data, which included 
only 2 trials (7). Even though the summary effect of CIMT on 
single measurements is well studied in several meta-analyses 
(5, 8, 9), the effect on groups of measurements in the Inter-
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national Classification of Functioning, Disability and Health 
(ICF) dimensions of body function, activity, and participation 
have only been partially examined (7). None of the analyses 
have combined more than one measurement from each study 
in their analysis. The ideal time to start the treatment after 
stroke is also uncertain. More information is therefore needed 
on the effect of CIMT within each ICF domain and the effect 
of follow-up and various factors on the therapy outcome. 
The aims of this systematic review were to combine the 
measurements used in CIMT trials in a valid manner accord-
ing to the ICF constructs in order to: (i) evaluate the effect of 
CIMT on arm motor function, arm motor activities, activities 
of daily living (ADL), and participation immediately after 
treatment and at 3–6 months follow-up; and (ii) assess how the 
reported effects are associated with the quality of the trial, the 
use of behavioural techniques, hours of training, the nature of 
the control group, and the time from stroke to trial enrolment. 
METhODS
Data sources 
PubMed, EMBASE, and CINAhL databases, as well as the Cochrane and 
PEDro Trial registers, were searched for empirical papers published from 
the inception of each database up to November 2012. The key words used 
for identifying CIMT trials were: CIMT, mCIMT, Forced use, constraint-
induced movement therapy. The term “Forced use” was included because 
this was the original term used in the preliminary CIMT experiments (2). 
From the PEDro trial register all records containing 1 of these keywords 
were reviewed. In the other database searches the CIMT search were 
combined with the following search terms for identifying stroke trials: 
stroke, hemiplegia, hemiparesis, hemiplegic, cerebrovascular accident, 
cerebrovascular accident (CvA), apoplexy, apoplexies or vascular acci-
dent brain. A research assistant read all the identified titles and excluded 
obviously irrelevant papers. In addition, the reference list from previous 
systematic reviews and included papers were assessed for relevant records. 
Two of the authors (GT and AA) read through the remaining abstracts and 
marked them as relevant, irrelevant, or potentially relevant based on the 
inclusion criteria. Full-text articles were retrieved for papers ranked as 
potentially relevant. Papers were included if: (i) a randomized controlled 
trial or quasi-randomized controlled trial was performed; (ii) patients were 
> 18 years old and had a diagnosis of ischaemic or haemorrhagic stroke; 
(iii) CIMT, mCIMT or forced use was compared with a control group; (iv) 
the treatment dose in the experimental group was 2–7 h of training per 
treatment day for a period of 8–28 days; and (v) there were more than 4 
subjects in the CIMT group. Papers were excluded if: (i) the CIMT group 
received additional interventions (e.g. botulinum toxin), or (ii) the control 
group received a different form of CIMT. Disagreements were resolved 
by a consensus discussion between the 2 assessors. 
Data extraction
Data were extracted from each paper to a coding form by a research 
assistant. Author name, publication year, and country were recorded 
for each paper. Pre-test, post-test, and 3–6 month follow-up data were 
extracted to compute the effect sizes. The PEDro score was obtained 
from the PEDro database (11) as a measure of trial quality. The PEDro 
Review group assess trials relevant for physiotherapy according and the 
results are available from the PEDro website (www.pedro.org.au). The 
PEDro scale is an 11-item assessment of trial quality based on whether 
the trial reports eligibility criteria, randomization procedure, concealed 
allocation, blinding of subjects, blinding of therapist, blinding of assessors, 
adequate follow-up, intention to treat analysis, between-group statistical 
comparisons and between-group comparability. The items assessing 
internal validity (2–11) is summed as a score for trial quality, with a pos-
sible range of 0–10. The reliability of the total PEDro score is described 
as “fair” to “good” (12). One trial did not have an official PEDro (13) 
score and was scored by collaboration between 2 of the authors (GT and 
AA). If the author stated explicitly that the groups compared in the trial 
were established by random allocation, then the trial was classified as a 
randomized controlled trial (RCT). If a trial did not state explicitly that it 
was randomized, or if the trial used a quasi-random method of allocation, 
it was classified as controlled clinical trial (CCT) (14). Trials in which 
the randomization was compromised were also classified as CCTs. Ac-
cording to our pre-specified criteria, we attempted to categorize the time 
since stroke into 3 categories (< 3, 3–12, and > 12 months) based on the 
trial inclusion criteria. however, in practice, this categorization was not 
possible because most trials included patients from 2 or more of these 
groups. Therefore, trials with a mean time since stroke of ≤ 45 days were 
classified as early intervention, while those with a mean time since stroke 
> 45 days was classified as sub-acute and chronic. The recording of the 
behavioural techniques (adherence-enhancing techniques and shaping) 
used in the CIMT was based on the description of the intervention. Shap-
ing was recorded as used if the exercises included motor tasks of short 
trials successively progressing in task difficulty, and included systematic 
feedback on performance. The number of adherence-enhancing techniques 
(behavioural contract, home diary, home practice, motor activity log) 
was noted. The nature of the control group was categorized into 4 (no 
treatment, usual care, calibrated intensive or other control treatment). The 
calibrated intensive category was used when the time in treatment in the 
control group was equal to that in the CIMT group. Control groups that 
received an unspecified normal treatment programme were defined as 
usual care. Other control treatments included non-calibrated experimental 
treatments. One of the authors transferred the data from the coding form to 
the computer program. During this process each value was cross-checked 
with the information from the actual paper.
Two authors (GT and AA) classified in consensus the outcome 
measures according to the International Classification of Functioning, 
Disability, and health (ICF) dimensions of body function, activity, and 
participation. The final classification is shown in Table I. Measurements 
used to examine the control of voluntary movement (ICF Chapter B760) 
(15), strength, or muscle tone were assigned to the arm motor function 
group (body function). The activity outcome dimension was divided 
into 2 groups. One group contained measures specifically designed to 
measure arm motor activity (Chapters d430, d440, and d445). The other 
group contained measures not specific to arm motor activity measur-
ing mobility (Chapter d4), self-care (Chapter d5), and domestic life 
(Chapter d6) (15). Measures belonging to this group were classified 
as ADL. One study reported the use of the MAL as a part of treatment 
(13); the MAL scores were therefore omitted from the analyses in the 
present study. If a study reported both the quality of movement and the 
amount of use scales, only the MAL amount of use scores was used for 
analysis. Measurements clearly measuring participation were classified 
in the participation group. 
Statistical analyses
The Comprehensive Meta-Analysis (CMA) version 2.2.064 software 
package was used for statistical analyses. The effect size for each 
outcome measures was calculated as a standardized mean difference 
(SMD) score, and was based on the post-test mean differences between 
the treatment and the control group, adjusted for the pre-test scores. 
If only post-data were available, the SMD was based on the post-test 
scores only. One study (16, 17) reported Cohen’s d’s for the outcomes; 
these values were entered directly into the program. A composite SMD 
was calculated and the variance of all the outcome measures within 
each of the 4 measurement domains (Table I) were then calculated in 
Microsoft Excel according to the formula given by Borenstein (18):
Where m is the number of measurements Y included in the composite 
variance, rij is the correlation between two measurements, Yi and Yj, 
and Vi and Vj is the respective variances of Yi and Yj.
var ( m ) = ( )2 var ( m
2
) = ( )2 ( m Vi
1
+ )1 Σ Y1 1 Σ Y1 1 Σ Σ (rij√Vi√Vj)m m m
i = 1 i = 1 i = 1 i ≠ j
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As none of the studies reported the correlations between the outcome 
measures, they were imputed based on the reported correlations from 
available studies. We used the highest correlation reported between the 
measurements in a stroke population, which is a conservative choice 
because high correlations produce wider confidence intervals than 
lower correlations (18). When correlations between measurements 
were not found, they were imputed based on correlations between 
scales of a similar nature. Random effects model meta-analysis was 
used to calculate the pooled SMDs, the 95% confidence intervals (95% 
CI), and the p-values within each domain. The combined effects in the 
4 studies that had 2 intervention or control-groups (19-22) were cal-
culated using the mean of selected comparisons function of the CMA. 
This procedure corrects the variance in order to take into account the 
relationship between the results in the 2 groups.
heterogeneity in effect sizes was examined by calculating a Q-test sta-
tistic (χ2 – distributed) and I2. The impact of trial quality, the behavioural 
techniques, and hours of training were examined by meta-regression. 
The impact of time since stroke, the shaping, and the control group were 
analysed by subgroup analysis, yielding a similar Q-test statistic. The 
variation of effect sizes within a subgroup was treated as random effects, 
while differences between sub-groups were treated as fixed effects. The 
study-to-study variance (t2) was estimated as common for all subgroups. 
Funnel plots were used to evaluate signs of publication bias. Analysis of 
sensitivity included: (i) one-study removal analyses to detect potential 
outliers heavily influencing the results; (ii) inspection of forest plots; 
(iii) analysing single elements and different cut-offs of the adherence 
enhancing techniques; (iv) sub-group analysis and meta-regression of 
moderators in the sub-acute and chronic group to evaluate the effect of 
removing the heterogenic early intervention group. 
RESULTS
Of 3,842 records initially screened 23 trials were included. The 
results from the literature research and selection of trials are 
shown in Fig. 1. Twelve papers reported supplemental analysis 
of another trial (16, 23–33). Three papers had insufficient data 
(34–36). Summary characteristics of the included trials are de-
scribed in Table II. The mean age of the patients in the different 
trials ranged from 48.7 to 71.7 years. The proportion of women 
varied between 15% and 60%. Four trials were categorized in 
the early intervention group. The mean time post-stroke in this 
group ranged from 6 to 41 days. The mean time since stroke 
in 19 trials in the sub-acute and chronic group ranged from 75 
days to 4.4 years. Twenty-one trials were classified as a RCT. 
Two trials were classified as a CCT, the first because of a non-
randomized method of allocation (13) and the second because 
11 patients who should have received the CIMT treatment were 
allocated to the control group and 10 controls received the 
CIMT treatment (37). For the latter study (37) the results from 
the per-protocol analysis were used. The PEDro score of the 
included trials ranged from 4 to 8 points. Regarding adherence 
enhancing techniques the home diary was most often reported 
(n = 8), followed by home practice (n = 4), behavioural contract 
(n = 4) and the use of MAL (n = 1). A calibrated intensive group 
was used as control group in most studies (n = 18), followed 
by usual care (n = 3) and other control treatment (n = 2). Seven 
Table I. Measurements used in constraint-induced movement therapy (CIMT) trials and included in the meta-analysis were classified as body function, 





ParticipationArm motor activity Activities of daily living
Action Research Arm Test 
Fugl-Meyer Motor Assessment
Motor Evaluation Scale for Arm in Stroke 
Patients
Modified Ashford Scale
Wolf motor function test – Grip strength
Grip strength ratio
Wolf motor function test – Strength
Actual Amount of Use Test
Grooved Pegboard Test
Nine-hole Peg Test 
16hPT
Motor Activity Log – Amount of use
Motor Activity Log – Quality of 
movement 
Stroke Impairment Scale – hand
Wolf motor function test – Time 




Nottingham Extended Activities of 
Daily Living
Rehabilitation Activities Profile
Stroke Impairment Scale – activities 
of daily living 
Stroke Impact Scale – 
Participation
Frenchay Activities Index 





Records identified through database 
searching 
Chinal – 785 
Cochrane trial register – 885 
EMBASE – 801 
Pedro trial register – 331 
Pubmed – 1,040 
Studies included in meta-analysis 
(n=23) 













• Not eligible (2) 
• Supplemental 
analysis of another 
trial (n=12) 





assessed for eligibility 
(n=40) 
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scales were classified as arm motor function measures, 9 as 
arm motor activity measures, 5 as ADL and 2 as measures of 
participation (Table I). The arm motor function data from one 
study (16) and the arm motor activity data from 2 studies (16, 
38) were based on post-treatment data only. Ten studies reported 
follow-up data. We found 6-, 4-, and 3-month follow-up data 
in 2 studies (39, 40), one study (4) and 6 studies, respectively. 
Meanwhile, 1 study (37) reported data from 1.5 and 12 months 
of follow-up. A composite of these data were used to substitute 
for the 3–6 month effects in this study. 
Effect on arm motor function
Sixteen trials (n = 714) used measures classified as arm motor 
function measures in the body function domain (4, 16, 19–22, 
37, 38, 41–48). Fig. 2 shows a small effect size in favour of 
the CIMT groups (SMD 0.28, 95% CI 0.11–0.44). The hetero-
geneity statistic was not significant (I2 = 11%, p = 0.331), and 
hence, none of the moderators interfered significantly with 
the results. Removing the trial classified as CCT (37) from the 
analysis did not interfere with the results (SMD 0.29, 95% CI 
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mean (SD) Trial quality Time since stroke CIMT group Control group















2 h/day, 15 days
(Calibrated intensive)















2 h/day, 15 days
(Calibrated intensive)















2 h/day, 15 days
(Calibrated intensive)


















Both: 2 h/day, 15 days
(Calibrated intensive)













2 h/day (T1/T2: Shaping/TP, 
hD; T1: Trunk restraint)
6 h constraint
15 days
Usual care, 2 h/day, 15 days
(Calibrated intensive)














Neurodevelopmental therapy,  
2 h/day, 15 days
(Calibrated intensive)
T: treatment group; C: control group; RCT: randomized controlled trial; CCT: controlled clinical trial; TP: task practice; BC: behavioural contract; 
hD: home diary; hSA: home assignments; MAL: motor activity log. ADL: activities of daily living
Fig. 2. Forest plot of the random effects meta-analysis of constraint-induced movement therapy (CIMT) on arm motor function immediately after treatment.
95% CI: 95% confidence interval; ARAT: Action Research Arm Test; FMA: Fugl-Meyer Motor Assessment; Grippit: Grippit strength ratio; MESUPES: 
Motor Evaluation Scale for Arm in Stroke; WMFT: Wolf Motor Function Test; S&C: Subacute and chronic. 
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group was analysed alone the effect size decreased (SMD 
0.22 95% CI 0.06–0.40) and the statistical heterogeneity was 
zero. In terms of 3–6 months follow-up, 7 studies (n = 421) 
reported motor function outcomes (4, 16, 19, 37, 41, 45, 46). 
The effect size was small and not significant (SMD 0.12, 95% 
CI –0.36–0.60). The symmetrical funnel plot indicated no risk 
of publication bias. 
Effect on arm motor activity
Twenty-two of the trials (n = 906) included measures of arm 
motor activities (4, 13, 16, 19–22, 37, 39–52). A moderate 
effect size was found for the effect of CIMT on arm motor 
activity (SMD 0.51, 95% CI 0.30–0.73). Fig. 3 shows the for-
est plot from the analysis. The heterogeneity was significant 
(I2 = 66%, p < 0.001). The 2 trials classified as CCT (13, 37) 
produced high effect sizes, but the overall result was still 
significant when these trials were removed from the analysis 
(SMD 0.46, 95% CI 0.23–0.68). A moderator analysis showed 
that the effect size among the early intervention trials was 
negative and significantly smaller (SMD –0.15, 95% CI –0.77 
to 0.47) than the other trials (SMD 0.61, 95% CI 0.38–0.83, 
Q = 5.2, p = 0.025). The heterogeneity in the effect was entirely 
explainable by the early intervention trials. When the sub-acute 
and chronic groups were examined alone, the I2 statistic was 
0% (p = 0.676). There was a slightly higher effect size in the 
9 interventions that did not include shaping (SMD 0.64, 95% 
CI 0.30–0.99) although it was not significantly higher than in 
the other interventions (SMD 0.42, 95% CI 0.12–0.71, Q = 1.0, 
p = 0.323). There was no significant differences between the 
18 trials that used a calibrated intensive control group and 
those 5 that controlled for usual care or other control treat-
ment (Q = 0.03, p = 0.872). Meta-regression did not show any 
significant effect of the PEDro score, the number of adherence 
techniques, or the duration of treatment. No signs of publica-
tion bias were found in the funnel plots. 
Nine trials reported follow-up data within the 3–6 month 
range for 478 patients (4, 16, 19, 37, 39–41, 45, 46). A moder-
ate effect size was reported on arm motor activity (SMD 0.41, 
95% CI 0.08–0.74). Considerable heterogeneity was observed 
between trials (I2 = 68%, p = 0.001). Following removal of the 
trial not using proper randomization (37), the effect size was no 
longer significant (SMD 0.33, 95% CI –0.02 to 0.67). A trend 
toward lower effect sizes was also evident in the early inter-
vention trials (SMD 0.14, 95% CI –0,50–0,79) compared with 
sub-acute and chronic trials (SMD 0.51, 95% CI 0,11–0,90), 
but the trend was not significant (Q = 0.88, p = 0.348). At this 
point, significant heterogeneity was seen among both the early 
(I2 = 75%, p = 0.017) and the sub-acute and chronic groups 
(I2 = 68%, p = 0.007). 
Effects on activities of daily living and participation
Ten trials (19, 21, 37, 39, 42, 43, 45, 48, 50, 52) reported the 
effects for 334 participants in the other activity measurements. 
The results from analysis of these trials are shown in Fig. 4. 
The effect size was smaller and not significant (SMD 0.19, 
95% CI –0.02–0.39). No statistical heterogeneity was ob-
served (I2 = 0%, p = 0.840) and, hence, none of the moderators 
influenced the effect size significantly. Only 2 studies (37, 39) 
reported follow-up data on the ADL (n = 90). The combined 
SMD was 0.06 (95% CI –0.33–0.45). Two studies (21, 50) 
reported post-treatment data for the participation category. 
A moderate, but non-significant, effect size was found (SMD 
Fig. 3. Forest plot of the random effects meta-analysis of constraint-induced movement therapy (CIMT) on arm motor activity immediately after 
treatment. The study from Dromerick et al. (19) is an outlier in the material. If this outlier is removed the standardized mean difference (SMD) increases 
to 0.59 (95% confidence interval (CI) 0.30–0.73); AAUT: Actual amount of use test; GPT: Groved pegboard test; MAL-a: Motor activity log - amount 
of use scale; SIS-hand: Stroke impact scale - hand function; WMFT-t: Wolf motor function test - time; lgWMFT-t: log transformed WMFT-t; WMFT-
fa: Wolf motor function test - functional ability; 16hPT: 16 hole peg test; S&C: Subacute and chronic. 
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0.23, 95% CI –0.24–0.71). Only one of these studies reported 
follow-up data. 
DISCUSSION
This meta-analysis found a small, but significant, effect of 
CIMT on arm motor function immediately after treatment in 
patients with stroke. A moderate effect on arm motor activity 
was also found immediately after treatment and at 3–6 months 
follow-up, although this effect was dependent on the inclu-
sion of one non-randomized trial. A large heterogeneity was 
observed among the studies in the arm motor activity domain, 
indicating that one or more factors could affect the treatment. 
The heterogeneity was predominately present in the rather few 
studies of early interventions. None of the other moderators 
(i.e. the quality of the trial, adherence-enhancing activities, 
shaping, the control group, or the duration of training) inter-
fered significantly with the effect sizes or were able to explain 
the heterogeneity in our material. Despite a low number of 
follow-up studies, our results do not anticipate lasting effects 
on arm motor function. The number of studies was too low to 
draw conclusions about the effect on ADL and participation. 
Our systematic meta-analysis included 23 studies and reported 
the synthesized effect sizes on up to 22 trials examining up to 906 
stroke patients. The largest former meta-analysis is a Cochrane 
review with a subsequent update (7, 10). Compared with our 
study they included less intensive CI interventions (less than 
2 h of training per day), as well fewer trials (n = 14) and fewer 
patients (n = 477). Of the 17 studies in our arm motor function 
analysis, only 3 were included in the former meta-analysis (7). 
Of the 23 studies in our arm motor activity analysis, only 6 were 
included in former analyses of arm motor function (10). Shi et 
al. (9) analysed CIMT lasting 0.5–3 h and constraint use of < 6 
h, where the effect was compared with traditional rehabilitation. 
This provides a slightly different analysis from the current one, 
which included interventions lasting from 2 to 7 h. In addition, 
most of the trials included in our review compared CIMT with 
an equally intensive treatment that would not automatically fit 
the description of traditional rehabilitation used by Shi.
Our effect size on arm motor function is lower than that 
reported by Sirtori et al. (7) (SMD 0.65), which might be ex-
plained by greater number of trials and the different measure-
ments included. In the arm motor activity domain our effect 
sizes are higher than reported by Corbetta et al. (10) on arm 
motor function (SMD 0.44) and lower than reported on per-
ceived arm use by Sirtori et al. (7) (SMD 1.16) and Paurala et 
al. (8) (SMD 0.85). Our arm motor activity domain included 
both these categories and this is probably the reason for the 
intermediate result. Our effect sizes on ADL immediately after 
treatment are similar to those calculated by Corbetta et al. (10) 
for the effect on disability (SMD 0.21, 95% CI –0.06 to 0.65). 
Meanwhile, their follow-up results were similar to ours. For the 
Functional Independence Measure, Peurala et al. (8) found a 
non-significant difference of 0.08 in 9 trials that included 267 
patients. This result is similar to our results for ADL.
One reason for the lower effect sizes in our analysis com-
pared with that of other analyses could be that we standardized 
the mean difference by the post-treatment standard deviation 
(SD). This decision was made a priori because the post-
treatment SD was thought to best reflect the variance at the 
time when the effect was evaluated. Some of the other studies 
have been standardized by the change-score SDs (7, 9), while 
other studies have mixed standardization by post-test SDs and 
change-score SDs (8). The pre-treatment variation was often 
smaller and could therefore yield larger effect sizes, which 
might be the reason for the lower SMDs in our study. Another 
reason for lower effect sizes might be our pre-specified inclu-
sion criteria that omitted a common CIMT modification that use 
0.5 h of training, 3 days a week for 10 weeks. The cut-off value 
of 2 h of therapy per day, and number of treatment days per 
week was chosen to lower the clinical heterogeneity between 
studies, but including these studies might have increased the 
effect sizes and the dose–response relationship between hours 
of treatment and treatment results.
A higher effect size was expected in trials with extensive use 
of behavioural techniques; however, this hypothesis was not 
supported by the current meta-analysis. A small experimental 
study has shown that the use of behavioural techniques may have 
Fig. 4. Forest plot of the random effects meta-analysis of constraint-induced movement therapy (CIMT) on activities of daily living immediately after 
treatment. 95% CI: 95% confidence interval; BI: Bartels index; FIM: Functional Independence Measure; RAP: Rehabilitation activities profile; RAPoccu: 
RAP-Occupation; SIS: Stroke Impact Scale; IADL: Instrumental activities of daily living; ADL: Activities of daily living; S&C: Subacute and chronic.
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a more long-lasting effect than treatments without them (53). 
Due to the low power of the follow-up analyses, we might have 
missed such an effect in our material, and this will be a concern 
for future research. In addition, some challenges were encoun-
tered in the sampling of the moderator variables. Comparing our 
definitions of shaping and adherence-enhancing activities with 
the descriptions in the reports was difficult; hence, the chance that 
behavioural techniques were misclassified is possible. However, 
research milieus known to emphasize these techniques describe 
them in detail (4, 13); thus, despite the lack of information some-
times observed, we believe that the behavioural techniques were 
probably correctly classified in most cases.
The present meta-analysis raised concerns regarding the 
large variation in treatment effects among the early interven-
tion trials. One of the early interventions trials (19) can be 
considered an outlier, which also contributed significantly 
to the heterogeneity between trials. The study had a 3-armed 
design with 2 treatment groups, which included patients very 
early after stroke. In terms of arm motor function, the study 
found that the Action Research Arm Test scores in the 2-h 
CIMT group were positively affected by the treatment, whereas 
those in the 3-h CIMT group were substantially negatively af-
fected compared with controls (19). This study used a different 
measurement (Stroke Impairment Scale – hand) than the other 
studies, and the pre-treatment scores for this measurement were 
not reported. As such, this may be one of the reasons for the 
large negative effect on arm motor activity shown in this study 
only. The variation in effect sizes between the early interven-
tion trials could indicate that the results of CIMT treatment at 
this stage may be more sensitive to intensity, other treatment 
components, or individual factors (54). Future studies on the 
efficacy of CIMT should therefore specifically compare early 
with later interventions in order to settle this question.
The new insight from our analyses is that there is a consistent 
effect of CIMT on arm motor function and arm motor activities 
in sub-acute and chronic patients. These studies represent a 
large variation in treatment dose, age groups, gender distribu-
tion, countries, and control groups. Nonetheless, the effect in 
the sub-acute and chronic group was still uniform. Even though 
the variation of effect sizes between the trials might be clini-
cally significant, this variation could be expected based on the 
sizes of the trials. Because of our definition of the sub-acute 
and chronic group (mean time from stroke > 45 days) this group 
will also include some patients included between 2 weeks and 
3 months post-stroke, not usually classified as sub-acute or 
chronic. Even though this interferes with the external validity 
the stable effect in this group does not suggest large implica-
tions from this classification. The post-treatment effect on arm 
motor activity was larger than the effect on arm motor function. 
CIMT have been developed to overcome learned non-use and 
increase the use of the more affected arm (2, 3), which prob-
ably explains why we observed a larger effect on arm motor 
activity measures compared with arm motor function measures. 
Another explanation may be that the measurement most often 
included in our arm motor activity category (i.e. MAL) was 
specifically designed to measure the effect of CIMT, and may 
therefore be more sensitive to the treatment effect (55). Our 
analysis also showed a moderate effect on arm motor activity 
3–6 months post-stroke; a result that has not been shown by 
former meta-analyses. Future studies should aim at explaining 
the heterogeneity in the follow-up results. 
Conclusion
By combining measurements in the ICF domains, we were 
able to show significant post-treatment effects of CIMT on arm 
motor function and arm motor activity and a follow-up effect 
on arm motor activity. In particular, stable effects immediately 
after treatment were detected in the sub-acute and chronic 
group. Future research should focus on the clinical and societal 
importance of these effects. More research is also needed to 
determine the effect of moderators in the treatment. We are 
concerned about the limited data and unpredictable effect from 
early intervention trials. We recommend that experiments 
with CIMT in the early stage after stroke be conducted with 
care. Significant emphasis should be placed on explaining the 
components that contribute to favourable or non-favourable 
effects from the treatment at this stage. 
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